These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32548088)

  • 1. Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease.
    Zhao R; Zhu M; Zhou S; Feng W; Chen H
    Front Chem; 2020; 8():407. PubMed ID: 32548088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload.
    Zhu M; Chen H; Zhou S; Zheng L; Li X; Chu R; Chen W; Wang B; Wang M; Chai Z; Feng W
    Nanotoxicology; 2021 Aug; 15(6):761-778. PubMed ID: 33961538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
    Ziamajidi N; Khaghani S; Hassanzadeh G; Vardasbi S; Ahmadian S; Nowrouzi A; Ghaffari SM; Abdirad A
    Food Chem Toxicol; 2013 Aug; 58():198-209. PubMed ID: 23603006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
    Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
    Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
    Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of soy isoflavone on hepatic steatosis in high fat-induced rats.
    Liu H; Zhong H; Leng L; Jiang Z
    J Clin Biochem Nutr; 2017 Sep; 61(2):85-90. PubMed ID: 28955124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
    Softic S; Cohen DE; Kahn CR
    Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
    Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
    J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patchouli Oil Attenuates High Fat Diet-induced Non-alcoholic Hepatic Steatosis.
    Xu N; Wu X; Luo HJ; Xu FF; Huang QH; Wu JZ; Gan YX; Li MY; Lai ZQ; Lin HR; Chen JN; Su ZR; Ai WP; Liu YH
    Planta Med; 2020 Mar; 86(4):255-266. PubMed ID: 31975362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules.
    Dang Y; Hao S; Zhou W; Zhang L; Ji G
    BMC Complement Altern Med; 2019 Jan; 19(1):8. PubMed ID: 30616587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis.
    Podszun MC; Alawad AS; Lingala S; Morris N; Huang WA; Yang S; Schoenfeld M; Rolt A; Ouwerkerk R; Valdez K; Umarova R; Ma Y; Fatima SZ; Lin DD; Mahajan LS; Samala N; Violet PC; Levine M; Shamburek R; Gharib AM; Kleiner DE; Garraffo HM; Cai H; Walter PJ; Rotman Y
    Redox Biol; 2020 Oct; 37():101710. PubMed ID: 32920226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis.
    Siculella L; Tocci R; Rochira A; Testini M; Gnoni A; Damiano F
    Biochim Biophys Acta; 2016 May; 1861(5):471-81. PubMed ID: 26869449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway.
    Tong J; Cong L; Jia Y; He BL; Guo Y; He J; Li D; Zou B; Li J
    Diabetes Metab Syndr Obes; 2022; 15():3285-3301. PubMed ID: 36325432
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Park M; Yoo JH; Lee YS; Lee HJ
    Nutrients; 2019 Feb; 11(3):. PubMed ID: 30813654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc oxide nanoparticles attenuate hepatic steatosis development in high-fat-diet fed mice through activated AMPK signaling axis.
    Dogra S; Kar AK; Girdhar K; Daniel PV; Chatterjee S; Choubey A; Ghosh S; Patnaik S; Ghosh D; Mondal P
    Nanomedicine; 2019 Apr; 17():210-222. PubMed ID: 30708053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.